Search results for: Takeda
Filter search results
Lung Cancer’s Biggest Test: How Can We Mobilise NGS Testing to Transform Lung Cancer Care?
7 December 2023, 12:00am
…this 90-minute webinar, we built on the results of the recently published report by OHE and Takeda: ‘The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe’….
Time to Tackle the Challenges around Combination Therapies for Cancer
29 March 2021
…OHE/Amgen paper on this was described in an OHE blog, and a paper is expected soon from a Takeda sponsored group looking at solutions in England. Competition law differs by…
Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology
1 February 2021
…to a workshop in November 2019 and a follow up report, with peer reviewed publications in the pipeline. We are also aware of the work initiated by Takeda, under the…
The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
2 June 2023
…for lung cancer in Europe This consulting report, ‘The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe’, was commissioned and funded by Takeda Pharmaceuticals America, Inc….
NGS testing for lung cancer across Europe still limited, despite clear case for adoption
10 July 2023
…A new report from the Office of Health Economics (OHE) and Takeda, published today, explores the status of access and uptake for NGS testing for lung cancer in Europe. Whilst…
Matthew Napier
11 January 2023
…policy. In November 2022, following an internship at Takeda UK as a health economics intern, where he undertook his dissertation project, he joined OHE. He has broad research experiences, including…